Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Operating Margin (2021 - 2025)

Historic Operating Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 12.24%.

  • Tarsus Pharmaceuticals' Operating Margin rose 400500.0% to 12.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.88%, marking a year-over-year increase of 845900.0%. This contributed to the annual value of 65.9% for FY2024, which is 7546300.0% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Operating Margin of 12.24% as of Q3 2025, which was up 400500.0% from 21.61% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Operating Margin registered a high of 33.07% during Q2 2021, and its lowest value of 4274.56% during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Operating Margin had a median value of 81.6% in 2024 and averaged 775.46%.
  • Examining YoY changes over the last 5 years, Tarsus Pharmaceuticals' Operating Margin showed a top increase of 41239500bps in 2022 and a maximum decrease of -36537500bps in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Operating Margin (Quarter) stood at 4274.56% in 2021, then soared by 96bps to 150.61% in 2022, then plummeted by -126bps to 339.94% in 2023, then surged by 89bps to 36.77% in 2024, then soared by 67bps to 12.24% in 2025.
  • Its Operating Margin was 12.24% in Q3 2025, compared to 21.61% in Q2 2025 and 33.55% in Q1 2025.